Halfway through its five-year, $10 million commitment, the Collaborative is bringing forth a host of both new therapeutic targets as well as drugs of interest to be evaluated in the clinic.

1,000+...Drugs screened for potential effectiveness against GBM tumors in laboratory models

75,000...combinations of compounds tested across different subtypes of GBM tumors

71...New laboratory models created, characterized, and validated to be used in drug testing

16...Potential new drugs/treatment approaches of interest identified for GBM

8...Potential new drugs/drug combinations prioritized for further preclinical to clinical advancement

4...Compounds identified as near-term clinical candidates

29...Papers and reviews published by Defeat GBM-funded researchers in high-impact scientific/medical journals

300+...The number of times these papers have been cited by other papers in the field

19...Novel targets for new treatment strategies identified

7...Potential new biomarkers identified to help predict and monitor patient response to GBM treatments

6...Areas identified as ripe for continued discovery/scientific efforts